References
- Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol 48, 1000–1007, 2008.
- Aller R, de Luis, DA, Fernandez L. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci 53, 1088–1092, 2008.
- American Diabetes Association. Diabetes Care 43, S14–S31, 2020.
- Bae JC, Cho YK, Lee WY, Seo H, Rhee EJ. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 105, 2389–2395, 2010.
- Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395, 2004.
- Das S, Singh SP, Parida PK, Mallik RN. Non-alcoholic fatty liver disease in subjects with type 2 diabetes mellitus and non-diabetics with special reference to insulin resistance and hepatic histopathological changes. Clin Res Rev 4, 226–229, 2010.
- Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P; AMD-Annals Study Group. The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes. J Diabetes Res 2016, 2931985, 2016.
- Garjani A, Safaeiyan A, Khoshbaten M. Association between platelet count as a noninvasive marker and ultrasono-graphic grading in patients with nonalcoholic fatty liver disease. Hepat Mon 15, e24449, 2015.
- Ghamar-Chehreh ME, Khedmat H, Amini M, Taheri S. Predictive factors for ultrasonographic grading of nonalcoholic fatty liver disease. Hepat Mon 12, e6860, 2012.
- Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22, 1141–1145, 2005.
- Jung CH, Lee B, Choi DH, Jung SH, Kim BY. Association of the grade of non-alcoholic fatty liver disease and glycated albumin to glycated haemoglobin ratio in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 125, 53–61, 2016.
- Junior WS, Nonino-Borges CB. Clinical predictors of different grades of nonalcoholic fatty liver disease. Obes Surg 22, 248–252, 2012.
- Kalra S, Vithalani M, Gulati G. Study of the prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 61, 448–453, 2013.
- Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, Kotze M. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 101, 477–480, 2011.
- Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int 41, 261–270, 2021.
- Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ. Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis. Hepatology 53, 726–736, 2011.
- Lopez-Velazquez JA, Silva-Vidal KV, Ponciano-Rodriguez G, Chavez-Tapia NC. The prevalence of non-alcoholic fatty liver disease in the Americas. Ann Hepatol 13, 166–178, 2014.
- Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol 20, 12956–12980, 2014.
- Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected non-alcoholic fatty liver disease. Hepatology 44, 874–880, 2006.
- Muzurovic E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 119, 154770, 2021.
- Muzurovic E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension 79, 1319–1326, 2022.
- Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53, 372–384, 2010.
- Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 123, 745–750, 2002.
- Sapmaz F, Uzman M, Basyigit S. Steatosis grade is the most important risk factor for development of endothelial dysfunction in NAFLD. Medicine (Baltimore) 95, e3280, 2016.
- Saremi Z, Rastgoo M, Mohammadifard M, Bijari B, Akbari E. Comparison of platelet number and function between nonalcoholic fatty liver disease and normal individuals. J Res Med Sci 22, 75, 2017.
- Shah NADM, Kadla SA, Mir IA, Khan BA, Shah AI, Shiekh SA, Bhat KJ. Diagnostic accuracy of FIB-4, APRI, AST/ALT ratio for prediction of fibrosis in chronic hepatitis B and C patients. Nigerian Journal of Gastroenterology and Hepatology 9, 55‒61, 2017.
- Smith BW, Adams LA. Non-alcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7, 456–465, 2011.
- Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41, 64–71, 2005.
- The University of Oxford. Diabetes trails unit. The Oxford centre of diabetes, Endocrinology and Metabolism https://www.dtu.ox.ac.uk/homacalculator/
- Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518–526, 2003.
- Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl) 134, 8–19, 2020.
- Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Non-invasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon 11, 103–106, 2011.
- Yoneda M, Fujii H, Sumida Y. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 46, 1300–1306, 2011.